Central Nervous System News and Research

RSS

Kendle offers BNA imaging technology for monitoring brain electro-physiological network activity

Kendle, a leading, global full-service clinical research organization, today announced it now offers Brain Network Activation imaging providing a non-invasive platform for mapping, monitoring and understanding brain electro-physiological network activity in response to cognitive or physiological stimuli. The BNA imaging technology was developed by ElMindA, a medical technology development company based in Herzliya, Israel.

15 Jun 2010

Orasi Medical signs agreement to study effect of Lundbeck CNS compounds on human brain

Orasi Medical today announced that it has entered an agreement with H. Lundbeck A/S to study the effect of Lundbeck central nervous system compounds on the human brain.

15 Jun 2010

Researchers establish link between air pollution and SDB

Researchers from Brigham and Women's Hospital and the Harvard School of Public Health have established the first link between air pollution and sleep-disordered breathing, a known cause of cardiovascular diseases.

15 Jun 2010

UCB announces availability of Vimpat oral solution formulation

UCB today announced the availability of an oral solution formulation of Vimpat- (lacosamide) C-V, an antiepileptic drug (AED) for add-on treatment of partial-onset seizures in people with epilepsy age 17 years and older. Vimpat 10 mg/mL solution is now available in U.S. pharmacies.

14 Jun 2010

MultiCell retains CDSS to manage MCT-125 Phase IIb clinical trial for PMSF in UK

MultiCell Technologies, Inc. has retained Clinical Development & Support Services, Ltd. (CDSS) of Cheshire, England to manage its planned Phase IIb clinical trial in the United Kingdom for MCT-125, the Company's lead drug candidate for treatment of primary multiple sclerosis-related fatigue (PMSF).

14 Jun 2010

Upsher-Smith commences global USL255 Phase III clinical trial for management of epilepsy

Upsher-Smith Laboratories, Inc. today announced the initiation of a global Phase III clinical trial for USL255 (extended-release topiramate), an internally developed program for the management of epilepsy in adults, using the company's proprietary formulation technology. USL255 is designed to provide convenient once-daily dosing and reduce fluctuations in topiramate blood levels observed with currently available topiramate options.

14 Jun 2010

Olfactory function tests could help in treating patient in early stages of PD

A fast, simple and non invasive test of the ability to smell may be an important tool to screen people who are likely to develop Parkinson's disease, in which motor symptoms only become evident at a later stage of the disease, a German scientist will tell the annual conference of the European Society of Human Genetics today (Saturday).

14 Jun 2010

White blood cells with receptors for both virus and nerve proteins may assault nerves after fighting infection

A virus infection can incite the body to attack its own nerve tissue by activating unusual, disease-fighting cells with receptors for both viral and nerve proteins. The dual-receptor observation suggests a way brain and spinal cord nerve damage might be triggered in susceptible young adults afflicted with multiple sclerosis.

11 Jun 2010

Universal Bioenergy, NDR Energy Group sponsor charitable event to raise funds for National Multiple Sclerosis Society

Universal Bioenergy Inc., an alternative energy company, and NDR Energy Group, announced today that they are sponsoring a major charitable event to help raise funds for the National Multiple Sclerosis Society.

11 Jun 2010

Interpretation of multiple gene function may hold clue to autism

Deciphering the functions of multiple rare genes may be at the core of understanding the genetic factors that cause autism spectrum disorders (ASDs), according to a new study published June 9 in the journal Nature by dozens of top autism researchers around the world, including Yale Child Study Center Director Fred R. Volkmar, M.D.

11 Jun 2010

Protein IL-10 removes Escherichia coli K1 bacterium from blood and reverses brain damage

A team of researchers at Childrens Hospital Los Angeles (CHLA), along with colleagues from the Keck School of Medicine of the University of Southern California and the Universite Auvergne, France, have discovered an important role for a small, naturally occurring protein called interleukin-10 (IL-10) in removing bacteria from the blood of infected mice and reversing damage to the brain.

11 Jun 2010

FDA advisory committee recommends approval of Novartis' FTY720 for relapsing MS

Today, an advisory committee of the US Food and Drug Administration (FDA) recommended approval of FTY720 (fingolimod) for the treatment of patients with relapsing multiple sclerosis, the most common form of the disease. The FDA has the option of seeking the advice of one of its advisory committees as it reviews and decides whether to approve a new treatment. The committee voted unanimously that FTY720 demonstrated substantial efficacy in treating relapsing remitting MS and that safety of the proposed 0.5 mg dose justified approval.

11 Jun 2010

Neutralizing inhibitory molecules does not improve regeneration in damaged spinal axons

Neuroscientists at the University of California, San Diego School of Medicine have found that removing three key inhibitory molecules from myelin - the insulating material that surrounds nerve cell fibers - does not significantly boost the ability of injured spinal axons to regenerate and restore themselves to full function.

10 Jun 2010

HDMA honors Upsher-Smith with two DIANA Awards

Upsher-Smith announced today that they are the recipients of two Distribution Industry Awards for Notable Achievements in Healthcare given by the Healthcare Distribution Management Association. The Company was presented with two DIANAs in the 'Best Overall Manufacturer' Awards category. Within this category, Upsher-Smith was the winner for the second time since 2008 of the 'Best Branded Pharmaceutical Company with Sales to Healthcare Distributors of less than $300 Million.'

10 Jun 2010

CoLucid's lasmiditan NAAMA effective in treatment of acute migraine attacks

CoLucid Pharmaceuticals, Inc.,, an innovative biotechnology company focusing on therapies for central nervous system disorders, today announced that its investigational first-in-class Neurally Acting Anti-Migraine Agent (NAAMA), lasmiditan (also known as COL-144), a selective 5-HT1F receptor agonist, was effective when given orally to treat acute migraine attacks, as documented in a Phase IIb study.

10 Jun 2010

Synteract joins Medidata's ASPire to Win channel partner program

Medidata Solutions, a leading global provider of SaaS-based clinical development solutions, today announced that Synteract has joined Medidata's ASPire to Win® channel partner program. A full-service contract research organization (CRO) with an increasing global presence and extensive experience working with emerging biotech, pharmaceutical and medical device sponsors, Synteract will offer services around Medidata Rave®, the market-leading electronic data capture (EDC) and clinical data management (CDM) solution.

9 Jun 2010

CXCR4 protein restores brain damage in multiple sclerosis patients

A protein that helps build the brain in infants and children may aid efforts to restore damage from multiple sclerosis (MS) and other neurodegenerative diseases, researchers at Washington University School of Medicine in St. Louis have found.

9 Jun 2010

Optical coherence tomography shows promise for multiple sclerosis diagnosis

A quick, painless eye measurement shows promise as a way to diagnose multiple sclerosis in its very early stages, and to track the effectiveness of treatments, researchers from UT Southwestern Medical Center have found in a multicenter study.

8 Jun 2010

UPMC Health Plan collaboration launches pediatric weight management program

A unique collaboration between UPMC Health Plan, Children's Community Pediatrics (CCP), and Children's Hospital of Pittsburgh of UPMC is utilizing a multidisciplinary team approach in the setting of the pediatrician's office to provide practical weight management strategies for children who are obese or overweight.

8 Jun 2010

CXCR4 protein may aid restore damage from MS and other neurodegenerative diseases: Researchers

A protein that helps build the brain in infants and children may aid efforts to restore damage from multiple sclerosis and other neurodegenerative diseases, researchers at Washington University School of Medicine in St. Louis have found.

8 Jun 2010

Central Nervous System News and Research

Kendle offers BNA imaging technology for monitoring brain electro-physiological network activity

Orasi Medical signs agreement to study effect of Lundbeck CNS compounds on human brain

Researchers establish link between air pollution and SDB

UCB announces availability of Vimpat oral solution formulation

MultiCell retains CDSS to manage MCT-125 Phase IIb clinical trial for PMSF in UK

Upsher-Smith commences global USL255 Phase III clinical trial for management of epilepsy

Olfactory function tests could help in treating patient in early stages of PD

White blood cells with receptors for both virus and nerve proteins may assault nerves after fighting infection

Universal Bioenergy, NDR Energy Group sponsor charitable event to raise funds for National Multiple Sclerosis Society

Interpretation of multiple gene function may hold clue to autism

Protein IL-10 removes Escherichia coli K1 bacterium from blood and reverses brain damage

FDA advisory committee recommends approval of Novartis' FTY720 for relapsing MS

Neutralizing inhibitory molecules does not improve regeneration in damaged spinal axons

HDMA honors Upsher-Smith with two DIANA Awards

CoLucid's lasmiditan NAAMA effective in treatment of acute migraine attacks

Synteract joins Medidata's ASPire to Win channel partner program

CXCR4 protein restores brain damage in multiple sclerosis patients

Optical coherence tomography shows promise for multiple sclerosis diagnosis

UPMC Health Plan collaboration launches pediatric weight management program

CXCR4 protein may aid restore damage from MS and other neurodegenerative diseases: Researchers

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News